Tirzepatide Once Weekly for the Treatment of Obesity

Summary

Phase 3 randomized double-blind trial comparing three once-weekly tirzepatide doses with placebo for 72 weeks in adults with obesity or overweight without diabetes.

Limitations

The trial excluded diabetes and used intensive trial follow-up. Gastrointestinal adverse events and treatment discontinuation affect tolerability, and sponsor involvement is relevant.

Linked peptides

• Tirzepatide